Abstract
Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Personalized medicine holds great promise for improving therapy outcomes by optimally targeting metabolic pathways.
Original language | English (US) |
---|---|
Pages (from-to) | 6-8 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 26 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2020 |
ASJC Scopus subject areas
- General Medicine